SpiroChem Acquires Cyclenium Pharma to Strengthen its Portfolio in Macrocyclic Therapeutics
Jun 6, 2023
Basel, Basel-Stadt Jun 6, 2023 (Issuewire.com) - SpiroChem, an Elite Contract Research Organization (CRO) headquartered in Basel, Switzerland, announced the acquisition of Cyclenium Pharma, a Montreal-based company specializing in the design and synthesis of macrocycle libraries using their cutting-edge CMRT ("smart") technology platform, enabling the efficient parallel construction of thousands of macrocycles under conformational control for use in the discovery of new bioactive molecules. The acquisition marks a significant milestone for SpiroChem as it expands its capabilities in the rapidly growing field of macrocyclic therapeutics.
Macrocycles are receiving renewed attention within the pharmaceutical industry as a promising therapeutic modality due to their unique properties and potential in targeting challenging disease targets and therapeutic areas. Cyclenium Pharma's unparalleled expertise in the design and synthesis of macrocycles, coupled with SpiroChem's pioneering advancements in conformationally restricted motifs, will create a powerful synergy, expanding the chemical space and possessing unparalleled medicinal chemistry utility covered by both companies' technology platforms. The resulting libraries will be even more attractive and differentiated, offering novel opportunities for hit generation and subsequent drug discovery and development projects.
By acquiring Cyclenium Pharma, SpiroChem establishes a strong presence in Canada and utilizes Cyclenium as a catalyst to expand its footprint and activities in North America. This strategic move serves as a relay of growth, allowing SpiroChem to tap into the vibrant Canadian life sciences ecosystem and leverage the diverse talent pool available in Montreal. SpiroChem also remains committed to its operations in Switzerland and continues to drive innovation from its headquarters in Basel. As part of its expansion plans, the company is actively evaluating options to further enhance its presence in Basel over the coming year.
"We are thrilled to announce the acquisition of Cyclenium Pharma," said Dr. Thomas Fessard, CEO of SpiroChem. "Their expertise in macrocycle design and synthesis perfectly complements our capabilities in generating novel conformationally restricted motifs and associated chemistry. Together, we will create an unrivalled library of macrocycles, enabling us to deliver innovative solutions to our customers and advance the field of drug discovery into a new dimension of chemical space. This acquisition also allows us to strengthen our position in North America, an important market for SpiroChem, and explore new avenues for growth in Basel."
"Becoming part of SpiroChem will permit broad access and full exploitation of the versatility and power of Cyclenium's unique technology, which we developed over the past decade for use against a variety of difficult drug targets" added Dr. Helmut Thomas, CEO and CSO of Cyclenium Pharma. "We are particularly excited about the synergistic potential of our joint novel platforms and the opportunities they offer in the application of macrocycles in pharmaceutical drug discovery and beyond."
The integration of Cyclenium Pharma into the SpiroChem family is expected to be seamless, with both companies working closely to ensure a smooth transition for employees, customers, and partners. SpiroChem remains dedicated to providing exceptional products, services, and value to the pharmaceutical and biotech industries, driving advancements in drug discovery and therapeutic development.
About SpiroChem:
SpiroChem is an Elite Contract Research Organization (CRO) operating in Basel, Switzerland. SpiroChem is covering the entire discovery chemistry value chain, from proprietary screening libraries (diverse high-sp3 fragments, covalent fragments, scaffolds for DELt), to design (FBDD, SBDD, CADD) and synthesis of bioactive molecules (Medicinal Chemistry, Medicinal Chemistry-Enabling platforms), all the way to early CMC (Route-Scouting). SpiroChem also provides unique services in the field of high-potent chemistry and ADC.
About Cyclenium Pharma:
Cyclenium Pharma is a Montreal-based company focused on drug discovery and development using its unique proprietary small molecule macrocycle CMRT technology platform. With a strong track record in hit and lead generation against difficult disease targets and rapid optimization of lead compounds through solid-phase parallel synthesis, Cyclenium Pharma plays a key role in advancing the field of drug discovery. By combining cutting-edge technology with groundbreaking structural designs, Cyclenium Pharma provides superb resources and expertise in support of the development of next-generation therapeutic modalities in a broad range of demanding therapeutic targets.
Media Contact
SpiroChem AG
+41616859504
Rosental area, WRO-1047-3 Mattenstrasse 24
Source :SpiroChem AG
This article was originally published by IssueWire. Read the original article here.
More News
The Fed Raised Rates. What Comes Next?
Kevin M. Warsh, the chairman of the Federal Reserve, on Wednesday left open-ended how much more interest rates may have to rise to tame inflation.
Uncontrolled AI could lead to 'silicon species' rivalling humans, warns Microsoft
Mustafa Suleyman says he believes rival AI firm Anthropic is in effect teaching Claude it "may be conscious".
Low-cost food pantry awarded £272k lottery grant
Oasis Hub Bath said the funding will cover its main operating costs over the next three years.
OpenAI reveals six more safety issues and unveils plan to disclose incidents
The firm also announced a new system to track, investigate and disclose cases of models misbehaving, or "misalignment".
The Documentary
Katy Watson explores Australia's relationship with China - partner, rival or 'frenemy'?
US interest rates raised for first time in three years
Rates were hiked in a unanimous decision despite fierce opposition from President Donald Trump, who had called for a cut.
Why Trump's hand-picked Fed chair defied him by raising interest rates
The 0.25% increase comes despite fierce opposition from the US president, who has called for rates to be cut.
EU chief backs plan for Canada to become 'associate member'
Trump, who has frequently clashed with Canada's PM, threatens to cut trade with the European Union in response to the proposal.
Snapchat open to putting time limits on teens, boss tells BBC
Evan Spiegel says it would be "an important step forward for the industry" in an interview with the BBC.
Would you buy branded clothing from your favourite tech firm?
Nvidia, OpenAI and Anthropic are all now selling their own limited edition fashion lines.
US Fed hikes rates for first time since 2023 as inflation stays sticky
US Fed hikes rates for first time since 2023 as inflation stays sticky
Watch: How will higher interest rates impact US consumers?
The BBC's Samira Hussain looks at the factors considered in the increase by the Federal Reserve and what it could mean for the US economy.
Inside Singapore's 'Fort Knox' for city's $2bn dirty money auction
The BBC goes inside a fortified storage facility to view luxury goods seized by police that are now up for auction.
Trump Ally Harold Hamm Strikes Venezuela Oil Deal
Mr. Hamm’s company, Continental Resources, has signed a preliminary deal with Venezuela’s state-owned oil company to develop and produce oil.
Takeaways From the Fed’s Decision to Raise Interest Rates
Kevin M. Warsh, the Federal Reserve chairman, said the bank acted to fight inflation that ‘is too high and has been for too long.’
The Quiet Way A.I. Is Hitting the Work Force
Lower wage growth and slower hiring in some sectors may be the result of artificial intelligence, especially for younger workers.
The World Economy Is Becoming Wary of the U.S.
America’s position of global economic stability is starting to look shakier as the Trump administration piles on debt and doubles down on sanctions.
Why the Fed Might Raise Interest Rates When Borrowing Costs Are Surging
Elevated interest rates have raised the cost of mortgages and car loans without dampening consumer spending.
Outkick Moves Past Its Clay Travis Era
Fox is revamping the sports site following the exit of its founder, Clay Travis. It’s hiring a writer who resigned from The Seattle Times over a column about transgender athletes.
Billions in Taxes Go Unpaid. Under Trump, the I.R.S. Won’t Say How Much.
The absence of the annual estimate on the tax gap could make it more difficult to assess whether more taxes are going unpaid since President Trump took office.
Bessent and Warsh Take On the Bond Bears
The Treasury secretary and the Federal Reserve chairman face similar tests: calming investors’ growing worries about inflation and deficits.
Global Oil Prices Could Hit Highest Levels in Months After Saudi Pipeline Attacks
Prolonged restrictions on exports could push oil prices even higher.
Henry Zeffman: Andy Burnham and his chancellor have a battle on their hands as the Budget approaches
The Budget is only six weeks away and the economy is undoubtedly the biggest challenge facing the prime minister.
Petrol and diesel price rises push UK inflation higher
Summer holidays and disruption to global oil supplies by the Middle East conflict stoked price growth.
Burnham rejects 'tax and spend socialist' comments
The prime minister insists he is prepared to take "difficult decisions" at next month's Budget.
Fed Meeting Is a Big Moment for the Bond Market
If the Fed opts against raising interest rates on Wednesday, investors will probably increase their forecasts for inflation, injecting new turmoil into the government bond market.
What's driving UK 'shoplifting crisis'?
The number of shoplifting offences recorded in England and Wales in 2025-26 is still above pre-pandemic levels.
Hong Kong's first five-year plan: Key economic and trade priorities
The Hong Kong Special Administrative Region has unveiled its first five-year plan for economic and social development (2026-2030) on Wednesday.
Graphics: What stood out in China's economy in August?
Graphics: What stood out in China's economy in August?
Witness the Pinglu Canal open to navigation!
The Pinglu Canal opens a faster gateway to the sea for China's Guangxi Zhuang Autonomous Region and southwest China's cargo.
Chinese films seek a bigger stage in North America
Chinese films are gaining momentum in overseas markets, with North America emerging as an important testing ground for their global appeal.
Hong Kong's first five-year plan signals a new path for future growth
The release of Hong Kong's first five-year plan marks an important milestone in the city's development. By building on its existing strengths and creating new opportunities through planning and innovation, the city can strengthen its competitiveness in a changing global environment.
Nanning and Guilin take center stage at the 23rd China-ASEAN Expo
The 23rd China-ASEAN Expo is set to open in Nanning, south China's Guangxi Zhuang Autonomous Region.
OpenAI boss says world 'right to be afraid' but should trust AI firms
Sam Altman and other tech CEOs say there are incentives to limit advancements in AI, as fears grow over the threats it poses to humanity.
Chinese mainland welcomes Taiwan to Pinglu Canal opportunities
Chinese mainland welcomes Taiwan to Pinglu Canal opportunities
What is happening to UK prices?
UK inflation rose in August, pushed up by higher petrol and diesel prices.
A ‘Shark’ of a Business Editor Steps Down
Ellen Pollock, who has spent nearly a decade in charge of the Business desk of The Times, is ready for a new challenge.
Security Guards Offer Protection, But Get Paid Little in Return
A recent high-profile shooting outside a mosque and rising threats to houses of worship have focused attention on security guards. Now, unions are pressing for better pay and training.
How to Use AI to Plan a Trip: Better Prompts for Travel Recommendations
Generic questions get generic answers, experts say, so to avoid mediocre recommendations, you’ll need to write smarter prompts. Follow these tips.
Reflecting on 175 Years of The New York Times
For dozens of editors and reporters, the anniversary of the first issue of The Times in 1851 has been a moment to look back.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.